I am an associate professor at the Copenhagen University and a Physiotherapist clinician-researcher with 20 years expertise in exercise for patients with cancer at the University Hospital of Copenhagen (Rigshospitalet). I am the cofounder of the “body and Cancer” and founder of the EXHALE program. I received my PhD from The University of Copenhagen in 2015, on the topic of Exercise and Advanced Stage Lung Cancer. My research area is exercise and lung cancer and I have developed exercise programs for patients with lung cancer in all stages (early and advance) and in different treatment modalities (diagnostic, surgery, chemotherapy, radiotherapy and immunotherapy). The focus is to prepare patients to treatment, optimizing functional capacity and maintaining or improving quality of life.

Dr. Donington is the chief of Thoracic Surgery and Professor of Surgery at the University of Chicago. She obtained her bachelor degree from the University of Michigan and her medical degree from Rush University. She completed general surgery training at Georgetown University, cardiothoracic training at the Mayo Clinic, and a surgical oncology fellowship in the Surgical Branch of the NCI. Her clinical interest is in the surgical treatment of non-small cell lung cancer with expertise in the use multimodality therapy for locally advanced disease, lung cancer clinical trials, and treatment options for medically high-risk patients with lung cancer.

Loretta Erhunmwunsee, M.D., F.A.C.S., Assistant Professor, Division of Thoracic Surgery and Division of Health Equities, is a health disparities researcher who focuses on evaluating the impact of social determinants on lung cancer risk, biology and screening. Supported by Cancer Center pilot funding and an institutional K12 grant, she has lead research that found that non-small cell lung cancer (NSCLC) patients who reside in areas with high levels of air pollution (PM2.5) have increased rates of an aggressive tumor mutation - TP53, which is linked to worse survival (Erhunmwunsee et al, CEBP 2021). Additionally, her studies have determined that several measures of neighborhood disadvantage increase the risk of KRAS somatic mutations, another marker of aggressive NSCLC biology. Previous work has shown a link between neighborhood socioeconomic status (SES) and survival of NSCLC patients as well (Erhunmwunsee et al, Cancer 2012). She also works with the Black Women’s Health study to explore the link between neighborhood SES and NSCLC risk in never smoking Black women. These studies suggest that adverse neighborhood conditions (pollution, disadvantage, SES) may explain why marginalized groups have worse lung cancer outcomes. Dr. Erhunmwunsee has also received funding from AstraZeneca to implement a Lung Cancer Screening (LCS) program at Federally Qualified Healthcare Centers (FQHC) in LA County. The study has shown that focused education of FQHC providers, staff and medical assistants improves provider comfort in discussing LCS and their ability to identify eligible LCS patients. This intervention has led to a greater than 1000-fold increase in LCS referrals at the community sites. A comprehensive systematic review on racial and socioeconomic disparities in lung cancer screening was recently written as well (Sosa et al, CA: A Cancer Journal for Clinicians 2021). Her future plans include (1) investigating the link between systemic racism-related factors and NSCLC mutational signature timing and (2) creating models to predict those at high risk for non-adherence to LCS.

Bishal Gyawali, MD, PhD is an associate professor in medical oncology and public health sciences and scientist in the Division of Cancer Care and Epidemiology, in Queen’s University, Kingston, Canada . He is also an affiliated faculty at the Program On Regulation, Therapeutics and Law in the Department of Medicine at Brigham and Women's Hospital, Boston, USA. He is also a member of the WHO Essential Medicine List for Cancer Drugs (2020-), ASCO’s Health Equity and Outcomes Committee (2021-2024), ESMO Global Policy Committee (2021-2022), ESMO-Magnitude of Clinical Benefit Scale working group (2019-) and ESMO-MCBS Quality of Life working group (2020-). Dr. Gyawali is also currently serving as a research consultant to the Nepal Health Research Council (2020-) and has previously served as a medical consultant for the not-for-profit Anticancer Fund, Belgium (2016-2018). He is in the editorial and advisory board for multiple medicine and oncology journals including Cell, JCO Global Oncology, JCO Oncology Practice and ecancer, has authored or co-authored more than a hundred peer-reviewed articles and is the recipient of the 2020 ASCO Conquer Cancer Foundation Global Oncology Young Investigator Award in Implementation Science. He was also awarded by the Government of Nepal with Young Health Researcher Award in 2020.

Dr. Gyawali’s areas of academic interests include cancer policy, evidence-based oncology, financial toxicities of cancer treatment, clinical trial methods, supportive care, and global oncology. He is an advocate of "cancer groundshot", a term he coined to imply that investment should be made on proven high-value interventions in cancer care that are easy to implement globally and are affordable. His research works involve health technology assessment impacting approval and funding decisions for cancer drugs, cancer policy including study of the economic consequences of cancer therapies and addressing disparities in cancer care. His research works have helped identify flaws in design of clinical trials that do not benefit patients or lead to misleading conclusions and identify low-value cancer drugs. These are tied to policy issues that help prioritize high-value interventions for patients, and help in shared understanding of risks and benefits of cancer therapeutics.

Dr. Gyawali tweets at @oncology_bg.

Paul Van Schil was born on July 7, 1957 in Antwerp, Belgium. He graduated from medical school with great honour in 1982 at the Antwerp University in Belgium. After completing his training in general surgery, he became a fellow in the department of cardiothoracic surgery at the Antonius Hospital, Nieuwegein, the Netherlands. His doctoral thesis was entitled “Bronchial sleeve resection for lung cancer: long-term results” (University of Nijmegen, the Netherlands, 1992).
In 1990 he became a staff member at the department of surgery of the Antwerp University Hospital. Currently, he is professor in thoracic and vascular surgery at the Faculty of Medicine, member of the Antwerp Surgical Training and Research Center (ASTARC) and consultant at the department of thoracic and vascular surgery of the Antwerp University Hospital.
From October 2013 till October 2014 he was president of the European Association for Cardio-thoracic Surgery (EACTS). In 2017 he became member of Board of Directors of the International Association for the Study of Lung Cancer (IASLC) and chair of the lung cancer domain of its Staging and Prognostic Factors Committee (SPFC). In September 2021 he will become president-elect of IASLC. Currently, he is an associate editor of the European Respiratory Journal, Journal of Thoracic Oncology and Acta Chirurgica Belgica. His main interests are thoracic and vascular surgery with a special emphasis on lung cancer staging and therapy, lung metastases, thymoma and mesothelioma.

Dr. Amy C. Moore serves as VP, Global Engagement and Patient Partnerships with LUNGevity Foundation, where she guides the organization’s efforts to build and sustain resources for patient communities—including programs for KRAS, EGFR, ALK, rare mutations, and small cell lung cancer—while building relationships with patient groups and professional societies globally. Additionally, Dr. Moore leads some of LUNGevity’s educational initiatives, including the organization’s COVID-19 programming, and plays an integral role in LUNGevity’s clinical trial transformation work. As an active member of the Science Team, Dr. Moore also serves as the lead for state-based policy directives.

As a trained virologist and cancer researcher with extensive experience in academia and over a decade in the nonprofit sector leading large research initiatives, Dr. Moore has published a number of peer-reviewed papers on a diverse range of topics from virology to cancer, including biomarker testing in NSCLC. She is also a recognized expert on issues at the intersection of COVID-19 and lung cancer and serves on a number of advisory boards.

Andreas Charalambous, BSc, MSc, PGCert (Research), PhD (Oncology Nursing), started his nursing career in 1995. He obtained his BSc in Nursing Science in 1999 by the Northumbria University (U.K), his MSc (Nursing Science) in 2002 and his PhD (Oncology Nursing) in 2008 from Middlesex University (UK). He has a proven track in academia since 2004. Ηe is the Chair of the Nursing Department at the Cyprus University of Technology where he works as an Associate Professor of Oncology and Palliative Care and he also holds the position of an Adjunct Professor at University of Turku (Finland). He is the founder and Past-President of the Cyprus Oncology Nursing Society, European Oncology Nursing Society (EONS) Past-President and European Cancer Organization President-Elect. He is also the Founder of the Cancer Nursing Fund (https://cancernurse.eu/cancer-nursing-fund/). He is involved in National and International research programs (HORIZON2020, ERASMUS+, COST) in various fields of cancer care. Examples of externally funded projects include: PI in the ERASMUS+ project PROLEPSIS (https://prolepsis.eu/) and PI (Cyprus team) in the ERAMUS+ project HERO (https://hero-erasmus.csl.gr/), PI (Cyprus team) in the HORIZON project INCISIVE (https://incisive-project.eu/)
He has published over 150 National and International publications in esteem journals. H-index 29 and i10-index 56
https://scholar.google.com/citations?hl=en&user=P13f8NsAAAAJ

Prior to ECPC, Antonella was the Executive Director of the Fit for Work Global Alliance, a multi-stakeholder coalition championing change in health and work policy. She has previously served as the Director of the Global Smoke-free Partnership of the American Cancer Society, leading a movement of over 100 members to coordinate the development of smoke-free laws in 40 countries. She holds a Master’s in Science and one in Business Administration. She currently represents ECPC on the Board of Pancreatic Cancer Europe, in which she is vice-chair, and she is also Board Member of All.Can.

Dr Meredith Giuliani MBBS, MEd, PhD, FRCPC is an Associate Professor in the Department of Radiation Oncology at the University of Toronto and the Director of Education at Princess Margaret Cancer Centre.
Dr Giuliani received her MBBS qualification from the University of London, England and she then competed her residency training in radiation oncology at the University of Toronto. She received her Master’s of Education from the Ontario Institute of Sciences in Education at the University of Toronto and her PhD from the School of Health Professions Education at Maastricht University. Her PhD focused on globalization and the influence of neocolonialism on oncology curricula. Her education research activity focuses on globalization, the influence of education on health systems and the intersection of education and health disparities. Her clinical interests include thoracic cancers with a focus on SBRT.

Graduated in Medicine by UFRGS in 2005. Fellow in Clinical Medicine (2008-2009) at Hospital Universitário de Santa Maria (Santa Maria - RS) and Clinical Oncology (2010-2013), Hospital São Lucas da PUC / RS (Porto Alegre - LOL ). Master's degree in Medicine and Health Sciences by the Postgraduate Program of the Pontifícia Universidade Católica do Rio Grande do Sul, during 2015-2017.

I currently work as a clinical oncologist at the Hospital São Lucas PUC / RS, and Grupo Oncoclínicas all in Porto Alegre. Medical Procedures Coordinator at Centro de Pesquisa em Oncologia – Hospital São Lucas PUC/RS - Porto Alegre / RS, and Thoracic Oncology Preceptor at the Clinical Oncology Residency of this hospital. Vice-president of the Brazilian Group of Thoracic Oncology, responsible for the organization of the main national events. Lecturer at national and international clinical oncology events. Researcher at the Centro de Pesquisa em Oncologia at Hospital São Lucas PUC / RS since 2012 from several clinical studies.